UCB (UCBJF) Raised to “Buy” at Zacks Investment Research
UCB (NASDAQ:UCBJF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday. The firm presently has a $97.00 target price on the stock. Zacks Investment Research‘s price objective would indicate a potential upside of 13.81% from the stock’s previous close.
According to Zacks, “UCB SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in providing therapy for central nervous system disorders, including epilepsy, diabetic neuropathic pain, sclerosis and Parkinson’s disease. It also provides therapy in the areas of oncology, immunology, inflammation, allergy and respiratory diseases. UCB delivers small and large molecule solutions to specialists for use in the treatment of severe diseases. “
UCB (NASDAQ:UCBJF) opened at 85.23 on Friday. The company has a market cap of $16.08 billion and a price-to-earnings ratio of 28.33. UCB has a 12-month low of $58.42 and a 12-month high of $86.75. The stock has a 50 day moving average price of $78.90 and a 200-day moving average price of $70.82.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.